ProCE Banner Activity

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Medical Oncology Perspective

Slideset Download

Download this slideset to review key data on the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for resectable early-stage NSCLC.

Released: August 26, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Patrick Forde, MD, PhD

Professor and Chair of Immuno-Oncology
Trinity College, Dublin Ireland
Johns Hopkins University
Baltimore, Maryland

Patrick Forde, MD, PhD: researcher (paid to institution): AstraZeneca, BioNTech, Bristol Myers Squibb, Novartis, Regeneron; consultant: Amgen, Ascendis, AstraZeneca, BioNTech, Bristol Myers Squibb, Curevac, G1, Genelux, Genentech, Gritstone, F Star, Flame, Fosun, Iteos, Janssen, Merck, Novartis, Regeneron, Sanofi, Synthekine, Tavotek, Teva.